Anti-phospholipid syndrome (APS) is defined by both clinical findings (recurrent arterial and/or venous thrombosis and recurrent fetal loss) and laboratory evidence of persistent anti-phospholipid antibodies (anti-cardiolipin antibodies, anti-β2-glycoprotein I antibodies, or LA activity). However, the precise mechanism responsible for arterial and/or venous thromboembolic complications in APS patients remains unclear. To clarify the association between the various types of anti-phospholipid antibodies (aPLs) and thrombotic complications in patients with systemic lupus erythematosus (SLE), we examined the prevalence of aPLs against various phospholipid-binding proteins (β2-glycoprotein I, prothrombin, protein C, protein S, and annexin V). We confirmed that the presence of both anti-β2-glycoprotein I and anti-prothrombin is closely related with arterial thrombosis, and that the presence of anti-protein S is closely related with venous thromboembolism. Furthermore, our in-vitro experiment suggests that anti-β2-glycoprotein I and anti-prothrombin may cooperate to promote platelet activation, and may be involved in the pathogenesis of arterial thrombosis. On the other hand, anti-protein S caused APC resistance, which may represent an important mechanism responsible for the development of venous thrombosis. Furthermore, our study showed that anti-β2-glycoprotein I causes persistently high expression of tissue factor on monocytes, and this may be involved in the pathogenesis of thromboembolic complications.
View full abstract